Coronavirus doorways, Epstein-Barr hideaways, family history takeaways, and more
By Ó³»´«Ã½ Communications
Credit: Len Rubenstein
Welcome to the April 24, 2020 installment of Research Roundup, a recurring snapshot of recent studies published by scientists at the Ó³»´«Ã½ and their collaborators.
Standard case-control genome-wide association studies (GWAS) ignore participants’ family histories of disease. Associate member Alkes Price in the Program in Medical and Population Genetics and graduate student Margaux Hujoel in the Stanley Center for Psychiatric Research developed a new association method known as LT-FH, which takes both case-control status and family history into account. Described in , the method attributes higher genetic liability to cases and controls with family history of disease, compared to those without. They used the method to analyze 12 diseases from the UK Biobank and found that it was more powerful in finding independent genome-wide-significant loci than standard GWAS methods.
The iron is hot
The recently described iron-dependent mechanism of cell death known as ferroptosis has been implicated in degenerative diseases and is a targetable vulnerability in several cancers. In a , core institute member Stuart Schreiber and postdoctoral associate Yilong Zou in the Chemical Biology and Therapeutics Science Program describe new insights into the lipid peroxidation state that drives ferroptosis and its role in disease contexts. They also discuss gaps in the understanding of ferroptosis and key challenges that have thus far limited the full potential of targeting ferroptosis for improving human health.
The secret to a virus’s hideout
Epstein-Barr virus causes several types of cancer, but hides from the immune system in a latent form in memory B cells. To learn how the virus remains latent, Rui Guo, Chang Jiang, John Doench, associate director of the Genetic Perturbation Platform, associate member Benjamin Gewurz (Brigham and Women’s Hospital), and colleagues did a genome-wide CRISPR-Cas9 screen in Burkitt lymphoma B cells. They found various host factors, all linked to the transcription factor MYC, that repress virus reactivation. Depleting MYC or factors important for MYC expression reactivated the virus, including in Burkitt xenografts. MYC blocks reactivation by binding a specific location along the virus’s genome that’s important for viral replication. The study, published in , suggests possible drug targets to maintain Burkitt latency.